Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Jeffrey Leiden, Anthony Shuber

Premium

Quest Diagnostics has elected Jeffrey Leiden to its Board of Directors. Leiden is the chairman, president, and CEO of Vertex Pharmaceuticals. Prior to that, he was a managing director at Clarus Ventures, and before that served as president, chief operating officer, and chief scientific officer at Abbott Laboratories. He has more than 20 years of scientific and commercial experience in the pharmaceutical and biotechnology industries as well as clinical and scientific experience as a cardiologist and molecular biologist.


Nabsys said that Anthony Shuber has joined the company as VP and chief scientific officer. He joins the firm from Ignyta, an oncology precision medicine firm, where he served as chief technology officer. Prior to joining Ignyta, Shuber was co-founder and CTO of Predictive Biosciences, and scientific co-founder of Exact Sciences. He also previously worked for Genzyme Genetics/Integrated Genetics and Genetics Institute.

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.